History
  • No items yet
midpage
Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.
817 F.3d 755
Fed. Cir.
2016
Read the full case

Background

  • Two District of Delaware patent-infringement actions under 35 U.S.C. § 271(e)(2) against Mylan for Ampyra and for Onglyza/Kombiglyze inferences of infringement by ANDA filings.
  • Mylan filed Rule 12(b)(2) motions arguing Delaware lacked general and specific personal jurisdiction; district judges denied.
  • Acorda/Alkermes and AstraZeneca argued Mylan’s ANDA filings and suit-related contacts established Delaware-specific jurisdiction; consent-based general jurisdiction via Delaware registration was disputed.
  • Mylan registers to do business in Delaware, designates an agent for service, and plans to direct sales into Delaware; plaintiffs also have Delaware ties (Delaware incorporation, subsidiary presence, or pending suits in Delaware).
  • Appeals focus on whether Delaware may exercise specific personal jurisdiction over Mylan; general jurisdiction via consent remains contested, with differing district court views.
  • This court affirms on the issue of specific personal jurisdiction; general jurisdiction discussion is not resolved in the majority opinion.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether Mylan is subject to specific personal jurisdiction in Delaware. Acorda/AstraZeneca assert suit-related contacts render Delaware-specific jurisdiction proper. Mylan contends no sufficient minimum contacts with Delaware for specific jurisdiction. Yes; Delaware has specific jurisdiction over Mylan.
Whether Mylan is subject to general personal jurisdiction in Delaware via consent by registering to do business. Delaware registration constitutes consent to general jurisdiction. Daimler overrules or limits consent-based general jurisdiction from registration. Not decided in majority; general-jurisdiction issue not resolved here.

Key Cases Cited

  • Calder v. Jones, 465 U.S. 783 (Supreme Court 1984) (specific jurisdiction based on targeted intentional acts)
  • Burger King Corp. v. Rudzewicz, 471 U.S. 462 (Supreme Court 1985) (minimum-contacts test linking forum, defendant, and litigation)
  • Walden v. Fiore, 571 U.S. 277 (Supreme Court 2014) (minimum contacts tied to suit-specific connections not just forum-state injury)
  • World-Wide Volkswagen Corp. v. Woodson, 444 U.S. 286 (Supreme Court 1980) (purposeful availment and reasonableness factors in venue)
  • International Shoe Co. v. Washington, 326 U.S. 310 (Supreme Court 1945) (establishes minimum contacts standard)
  • Daimler AG v. Bauman, 134 S. Ct. 746 (Supreme Court 2014) (limits on general jurisdiction; discusses consent distinction)
  • Pennsylvania Fire Insurance Co. v. Gold Issue Mining & Milling Co., 243 U.S. 93 (Supreme Court 1917) (consent through registration historically recognized as basis for general jurisdiction)
  • Sternberg v. O’Neil, 550 A.2d 1105 (Del. 1988) (Delaware registration consent analysis for general jurisdiction)
Read the full case

Case Details

Case Name: Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.
Court Name: Court of Appeals for the Federal Circuit
Date Published: Mar 18, 2016
Citation: 817 F.3d 755
Docket Number: 2015-1456, 2015-1460
Court Abbreviation: Fed. Cir.